{"name":"NuBiyota","slug":"nubiyota","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MET-3","genericName":"MET-3","slug":"met-3","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"MET-3","genericName":"MET-3","slug":"met-3","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPTC1zQlJYVlpPOVcwdWtDbDUwNDB1ZnliMkFCeDBKbU9UUGVnUnRhR3VaeDZ6OFJHcnZYM3JBREJEdkpzbk1acVFkLU5jQjB1VWhDMFpRSWFKcGVLRUYwMG8zdXJ1X1RfRmRwM1NqZWdjRTktSWRobllwZ1Z0Nkd2QVlfTHRXcGoxMlJobE5FOS0xVjBYaGZxUzFaVl9nNUJsSFF6TkxuTDlhd0lsclNaQktVVUVpMDRVMDI2UWFGaVhOOVNvQU9QNnUxdlVxWTBuUFdKdkNMZ2hZS2Q4?oc=5","date":"2023-02-13","type":"pipeline","source":"Rockland County Business Journal","summary":"Hudson Valley iCampus, former Pfizer Foothold, Continues To Attract Pharma & Tech On Still Mostly-Vacant Spread - Rockland County Business Journal","headline":"Hudson Valley iCampus, former Pfizer Foothold, Continues To Attract Pharma & Tech On Still Mostly-Vacant Spread","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOSFlENGJxaEhRWDU4SmhWS19oMlFKRVZtZkFBZTVDSno1OC1SS0p0X3gzc0tFTlZtYnBXaUF5LWQ0ajNoZTZqR3MxMWhNSHRJOXhOdzUyU1QxZlhzTzdwX2dTeWxBWTE4c3V2bUxlUzVOMG52TmtUeFJlc2NlZEN2X3RpdFppOXRmTjJHTg?oc=5","date":"2022-08-26","type":"deal","source":"BioPharma Dive","summary":"Takeda ends deal with Finch as bumpy ride continues for microbiome drugs - BioPharma Dive","headline":"Takeda ends deal with Finch as bumpy ride continues for microbiome drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPQ3NpTV9aUFJoamx5cFVXcUtiN01nS1dtcGhuejFqUEsxbTFzQVRsRXlmQXQzcWJwdEV0Nm1OYkdqTnFSNEhwbmtqWUExZXdtcEhmN2FBenZ0NmdHYTdZMW9SRWNydlp4NlVzRjVCMm1BMFcwSGZ5VGU0VEJDZzFjU2NCeHdRWUFWWjU2dG9TdzQtSHZVQk40eU40Z3N3dw?oc=5","date":"2019-01-18","type":"pipeline","source":"The Journal News | lohud.com","summary":"Pearl River campus gets new pharma tenant, plans to hire 100 - The Journal News | lohud.com","headline":"Pearl River campus gets new pharma tenant, plans to hire 100 - The Journal News | lohud.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOb20wRkFXTE9iUXdVZnowdGFadjdCY21IV3ItYTFib2hINFhCdVBfOUJZNzVHWGtBbi13cHJVYjNBMjVMbmtRekUwTzJwS3Z5M2h6WVctMk9FYl91clJya3hpOEpLZHM2emhRbHBZUkxPZFFFMHZBT1c1cnU3Vnlub3VhbzBWNkE1ejNXc3JRWjZEckVxYzJwY0Rtbzh3bE53d1pRNE5ieXFCUERNMWJJTUp3THNRTnJ3bUlYLVU5MFZyTVVFZXpBX1d3TExNc1E1SUo4?oc=5","date":"2017-12-08","type":"pipeline","source":"The Journal News | lohud.com","summary":"Pearl River: Former Pfizer campus gets new biotech tenant - The Journal News | lohud.com","headline":"Pearl River: Former Pfizer campus gets new biotech tenant - The Journal News | lohud.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOOXFtNEtUNngtOExSckxFYkY1UFg0MDRHWG5BZDZVUk1aZklDZXRzb1pnempQTmVJQVJ0d2h5SW9QakFraXVqbVBrT1N5NW50djk5bzdXYTM2ajZkMHlHRTF4dk1jcGVLbWUzY05iWC10a0dEWWVsYzg3Zkc0UEVKWF9xU2RnNk1xVGZ2ZUhPc0p1cVdMUkFDSC1tT3dwaUhLY1pDazB3eXhxT1dJSUF5b1FnRDJEeXBtMWU3OVNEXzBlNHc?oc=5","date":"2017-04-14","type":"trial","source":"Fierce Pharma","summary":"FiercePharmaAsia—Mylan plant’s data issue, Takeda’s deal spree, China’s hardened trial data policy - Fierce Pharma","headline":"FiercePharmaAsia—Mylan plant’s data issue, Takeda’s deal spree, China’s hardened trial data policy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPb1VYMUcxUTJ0MFhvZE5lY3ZzVlIwalZEZkRvcjFkSlNlc1p6d291OWU1VU9ZTDd0WnRjdUVZVWFkdktfbHJGdlp2b2tQUFMzSXV3TVFBdHdNeGNKNUdhd0JOaHJMOGFzTUlZWUUtTGxxVW4wS0xSQThFVVA0eUYxLTFBc0V6UVhoWk1KREVlLWprSVByMmUwTkdvQQ?oc=5","date":"2017-04-11","type":"deal","source":"Fierce Biotech","summary":"NuBiyota pact continues Takeda’s GI, microbiome deal blitz - Fierce Biotech","headline":"NuBiyota pact continues Takeda’s GI, microbiome deal blitz","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}